These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36237332)

  • 1. Histone lysine methylation patterns in prostate cancer microenvironment infiltration: Integrated bioinformatic analysis and histological validation.
    Quan Y; Zhang X; Wang M; Ping H
    Front Oncol; 2022; 12():981226. PubMed ID: 36237332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
    Quan Y; Zhang X; Ping H
    Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation.
    Zhou W; Lin J; Liu J; Zhang R; Fan A; Xie Q; Hong L; Fan D
    Aging (Albany NY); 2023 Feb; 15(3):846-865. PubMed ID: 36791151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
    Xu Z; Chen S; Zhang Y; Liu R; Chen M
    Front Immunol; 2022; 13():869759. PubMed ID: 35603206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
    Chen L; Zhang M; Zhou J; Zhang L; Liang C
    Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 7. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.
    Su Q; Zhu Y; He B; Dai B; Mu W; Tian J
    Eur J Med Res; 2023 Nov; 28(1):545. PubMed ID: 38017548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database.
    Xu M; Li Y; Li W; Zhao Q; Zhang Q; Le K; Huang Z; Yi P
    Front Med (Lausanne); 2020; 7():64. PubMed ID: 32195260
    [No Abstract]   [Full Text] [Related]  

  • 10. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
    Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
    Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
    Luo C; Chen J; Chen L
    Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UQCRB and LBH are correlated with Gleason score progression in prostate cancer: Spatial transcriptomics and experimental validation.
    Quan Y; Zhang H; Wang M; Ping H
    Comput Struct Biotechnol J; 2024 Dec; 23():3315-3326. PubMed ID: 39310280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Prostate Cancer Risk Genetics Biomarkers Based on Intergraded Bioinformatics Analysis.
    Liang X; Wang Y; Pei L; Tan X; Dong C
    Front Surg; 2022; 9():856446. PubMed ID: 35372462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m
    Liang Y; Zhang X; Ma C; Hu J
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant Evaluation and Clinical Prognostic Values of M6A RNA Methylation Regulators in Prostate Cancer.
    Zhang Q; Luan J; Song L; Wei X; Xia J; Song N
    J Cancer; 2021; 12(12):3575-3586. PubMed ID: 33995635
    [No Abstract]   [Full Text] [Related]  

  • 18. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
    Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
    Front Immunol; 2022; 13():914577. PubMed ID: 35757739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.
    Jiao M; Zhang F; Teng W; Zhou C
    Int J Gen Med; 2022; 15():3003-3030. PubMed ID: 35313552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.